Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07420751 · ClinicalTrials.gov registry record · NA
Assessment of Patient Experience With Auto-Captioning Glasses in NF2-Related-Schwannomatosis
A NA study of NF2-related Schwannomatosis, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07420751: Recruiting NA study of NF2-related Schwannomatosis, sponsored by Massachusetts General Hospital.
NCT07420751 is a NA study of NF2-related Schwannomatosis that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07420751, a NA study of NF2-related Schwannomatosis, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to investigate the usability of auto-captioning glasses for adults diagnosed with NF2-related schwannomatosis and loss of hearing. The primary objective of the study is to determine the feasibility and acceptability of auto-captioning glasses in this population. Participants will be asked to: * Use the glasses at their discretion for 12 weeks * Report their feedback at 3 and 12 week timepoints via online surveys and remote qualitative interviews
Primary Outcome
Used to assess the usability of the auto-captioning glasses, scored from 0-100, with higher scores indicating higher usability.
Conditions Studied
Interventions
- DEVICE Auto-captioning Glasses
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-02 |
| Est. Completion | 2026-12 |
| Phase | NA |
What NCT07420751 shows while recruiting
NCT07420751 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with NF2-related Schwannomatosis appearing as the primary indexed condition, and to 1 intervention - of which Auto-captioning Glasses is the first listed.
NCT07420751 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07420751 about?
NCT07420751 is a clinical study titled "Assessment of Patient Experience With Auto-Captioning Glasses in NF2-Related-Schwannomatosis". The goal of this clinical trial is to investigate the usability of auto-captioning glasses for adults diagnosed with NF2-related schwannomatosis and loss of hearing. The primary objective of the study is to determine the feasibility and acceptability of auto-captioning glasses in this population. P...
What is the current status of trial NCT07420751?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2026-02. Estimated completion is 2026-12.
What conditions does trial NCT07420751 study?
This clinical trial studies the following conditions: NF2-related Schwannomatosis.
What interventions are being tested in trial NCT07420751?
The interventions under investigation include: Auto-captioning Glasses (DEVICE).
Who is sponsoring clinical trial NCT07420751?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07420751 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07420751's enrollment target sits among peer trials
20 1768th of 2000 higher than 140 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia